Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | TCRR | Common Stock | Other | -4.39M | -100% | 0 | Jun 1, 2023 | By LP | F1, F2, F3 |
Kevin Tang is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Id | Content |
---|---|
F1 | This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics, Inc. (the "Issuer"), Adaptimmune Therapeutics plc ("Parent"), and CM Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Issuer, Parent, and Merger Sub, to which Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 1.5117 American Depository Shares of Parent ("Parent ADS"), representing six ordinary shares of Parent. |
F2 | The Reporting Persons received 1.5117 Parent ADSs in exchange for each Share cancelled in connection with the Merger. |
F3 | The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. |